Urologic Oncology   

For example, a patient that received an MRI after biopsy that demonstrates a PIRADS 5 lesion in anterior TZ which likely was not sampled on biopsy. Wo...

Which patients specifically benefit from both mpMRI and PET-PSMA?

Has this recent retrospective analysis published in Lancet Oncology changed your practice?

Will you use it rather than a carboplatin-containing regimen?

Based on GI regimen or urothelial carcinoma regimens?

How would you treat such a patient? 

Confirmed no urothelial carcinoma and muscle in specimen without involvement. 

Does this raise concerns about the efficacy of adjuvant immune checkpoint inhibition? Are any preliminary results from AMBASSADOR (adjuvant pembrolizu...

The forest plot from CheckMate 274 did not show a benefit for such patients? How would you select between adjuvant chemotherapy and adjuvant nivoluma...

Is a 3 month delay too long in someone who had postoperative complications?

Are there other high or very high risk features that would also contribute to your decision making?

Is there a benefit to cytoreductive nephrectomy if residual metastases are not resected? Any benefit to extending surgery to other metastatic sites?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 

What neoadjuvant or adjuvant therapy would you give?

Wouldn't lymph node dissection improve sensitivity of staging and inform adjuvant treatment decisions?

Should cystectomy remain standard of care? (Recently debated in JAMA Oncology: http://jamanetwork.com/journals/jamaoncology/article-abstract/2520055...

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...